<DOC>
	<DOC>NCT00920634</DOC>
	<brief_summary>The main purpose of this investigation is to collect information about safety and efficacy of Follistim Injection from actual clinical use to induce ovulation in patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.</brief_summary>
	<brief_title>Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Anovulation</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Patients who underwent IVF Patients with tumors of ovary, breast, uterus, pituitary or hypothalamus Pregnant or possible pregnant women, or lactating women Patients with undiagnosed atypical vaginal bleeding Patients with a history of hypersensitivity to any of the ingredients of this product Patients with ovarian cysts or enlarged ovaries, not related to polycystic ovarian disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>